Caesarea, Israel – March 9, 2026
A newly updated 2026 Resource Guide from the American Society of Breast Surgeons (ASBrS) recommends the use of cryoablation as a treatment option for selected patients with biologically low-risk early-stage breast cancer, marking a significant step forward in the adoption of minimally invasive tumor-destruction technologies in oncology care. The updated clinical guidance highlights the growing clinical acceptance of cryoablation procedures that destroy tumors through controlled freezing, offering an alternative to surgical tumor removal for certain patient populations. The update also reinforces the clinical value of ProSense® cryoablation technology, which received U.S. FDA marketing clearance in October 2025 for the treatment of low-risk breast cancer in women aged 70 years and older with small tumors treated alongside endocrine therapy.
Updated Clinical Guidance Supports Cryoablation Therapy
The American Society of Breast Surgeons’ updated 2026 clinical resource guide now recognizes cryoablation as an appropriate treatment option for carefully selected patients with low-risk early-stage breast cancer, reflecting growing evidence supporting the safety and effectiveness of this minimally invasive approach. The recommendation builds on data from the ICE3 clinical study, as well as a favorable benefit-risk evaluation from a U.S. FDA advisory panel, which concluded that cryoablation technology provides meaningful clinical outcomes for specific patient groups.
Cryoablation works by freezing tumor tissue using extremely low temperatures, causing cancer cells to be destroyed while minimizing damage to surrounding healthy tissue. This technique allows physicians to treat tumors without traditional surgical excision, significantly reducing procedure complexity and recovery time for patients. The updated ASBrS guidance emphasizes that cryoablation should be considered within a multidisciplinary treatment strategy, involving oncologists, surgeons, and radiologists to ensure optimal patient outcomes.
The new recommendation aligns with a broader shift in modern oncology toward breast-conserving and minimally invasive treatment approaches, particularly for older patients with low-risk disease profiles. These strategies prioritize reduced surgical trauma, improved cosmetic outcomes, and faster patient recovery, while maintaining effective local tumor control.
Advertisement
ProSense Cryoablation Technology Expands Treatment Options
The ProSense® Cryoablation System, developed by IceCure Medical, is currently the first and only FDA-cleared medical device specifically authorized for the treatment of low-risk breast cancer in elderly patients meeting defined clinical criteria. The technology uses liquid nitrogen-based cryosurgical techniques to create lethal freezing zones that destroy tumor cells, offering a non-surgical option for patients who may not be candidates for traditional tumor removal procedures.
Unlike conventional surgery, cryoablation procedures can often be performed in outpatient or office-based settings, significantly reducing hospitalization and healthcare costs. The technology also offers several clinical advantages, including reduced pain, minimal scarring, shorter recovery periods, and lower complication risks, making it an attractive option for patients and physicians alike.
The ProSense system is designed to precisely target and freeze cancerous tissue while preserving surrounding structures, enabling highly controlled treatment outcomes. In addition to breast cancer applications, cryoablation technologies are also being investigated and used for the treatment of tumors in the kidney, lung, liver, and bone, demonstrating the broader potential of this minimally invasive technology platform.
Growing Role of Minimally Invasive Cancer Treatments
The updated ASBrS recommendation highlights the growing role of minimally invasive technologies in modern cancer care, particularly as healthcare providers seek treatments that combine clinical effectiveness with improved patient quality of life. Cryoablation technology represents one of several emerging approaches aimed at reducing the need for traditional surgical interventions while maintaining strong oncological outcomes.
According to clinical data referenced in the updated resource guide, cryoablation could potentially benefit approximately 200,000 women annually in the United States, including tens of thousands of patients with early-stage breast cancer who meet eligibility criteria for non-surgical treatment options.
This shift toward minimally invasive treatment methods reflects a broader transformation in oncology practice, where precision medicine, imaging-guided procedures, and advanced medical devices are increasingly used to personalize patient care. By integrating technologies such as cryoablation with endocrine therapy and other targeted treatments, clinicians can develop individualized treatment plans tailored to each patient’s tumor characteristics and overall health status.
The updated ASBrS guidance therefore represents an important milestone for image-guided tumor ablation technologies, supporting their role as part of the evolving toolkit for breast cancer management. As clinical evidence continues to grow and adoption expands globally, cryoablation may become an increasingly important alternative to traditional surgery in selected breast cancer patients, offering a less invasive yet effective treatment pathway.
z
Source: IceCure Medical press release
